- Home
- QTTB vs WBX Comparison
QTTB vs WBX Comparison
Compare QTTB & WBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | WBX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Spain |
| Employees | N/A | 696 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.0M | 50.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | QTTB | WBX |
|---|---|---|
| Price | $6.20 | $2.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $4.75 |
| AVG Volume (30 Days) | ★ 325.4K | 17.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | $18.10 |
| Revenue Next Year | N/A | $94.11 |
| P/E Ratio | $2.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $0.23 |
| 52 Week High | $8.05 | $7.83 |
Technical Indicators
Market Signals| Indicator | QTTB | WBX |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 53.41 |
| Support Level | $5.51 | $2.84 |
| Resistance Level | $6.37 | $3.31 |
| Average True Range (ATR) | 0.76 | 0.27 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 42.46 | 53.92 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.